Kuros Biosciences【0RHR】銘柄情報

Kuros Biosciences AG (0RHR) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

8.56

( - )

買値

8.56

売値

8.56

出来高

14,410

平均取引量 (3 か月)

CHF 194,522

財務取引量

0.00 日の範囲 0.00

8.56 52 週間の範囲 8.56

時価総額

337.767M

企業価値

920.707M

前日終値

8.56

始値

時刻

3659

21.78498

(O)

最終取引時間

VWAP

歳入

146.06M

純利益

2.55M

発行済株式数

39,458,787

浮動株比率 (%)

73.92%

機関投資家保有比率 (%)

17.00%

配当利回り

PER

396.66

株価売上高倍率 (PSR)

6.43

1 株当たり利益 (EPS)

0.06

ベータ

0.74

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Gran... Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland. 詳細を表示

セクター

Health Care

業界

ウェブサイト

kurosbio.com

本社

Schlieren, Switzerland

設立

2026

Kuros Biosciences AG is listed in the Health Care sector of the ロンドン証券取引所 with ticker 0RHR. The last closing price for Kuros Biosciences was CHF8.56. Over the last year, Kuros Biosciences shares have traded in a share price range of CHF 8.56 to CHF 8.56.

Kuros Biosciences currently has 39,458,787 shares in issue. The market capitalisation of Kuros Biosciences is CHF337.77 million. Kuros Biosciences has a price to earnings ratio (PE ratio) of 396.66.

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Kuros...

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of...

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Annual General Meeting of Kuros Biosciences approves all resolutions...

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Ad hoc announcement pursuant to Article 53 of the...

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Ad-hoc announcement pursuant to Article 53 of the...

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences Kuros Biosciences to provide investor updateat Octavian and...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Kuros Biosciences to present at the Piper Sandler 37th Annual...

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 Ad hoc...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Kuros Biosciences debuts commercial launch of MagnetOs...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	8.56	8.56	8.56	16816	8.56	DE
52	8.56	8.56	8.56	16317	8.56	DE
156	8.56	8.56	8.56	10379	8.56	DE
260	8.56	8.56	8.56	6050	8.56	DE

0RHR - Frequently Asked Questions (FAQ)

What is the current Kuros Biosciences AG share price?

The current share price of Kuros Biosciences AG is CHF 8.56

How many Kuros Biosciences AG shares are in issue?

Kuros Biosciences AG has 39,458,787 shares in issue

What is the market cap of Kuros Biosciences AG?

The market capitalisation of Kuros Biosciences AG is CHF 337.77M

What is the 1 year trading range for Kuros Biosciences AG share price?

Kuros Biosciences AG has traded in the range of CHF 8.56 to CHF 8.56 during the past year

What is the PE ratio of Kuros Biosciences AG?

The price to earnings ratio of Kuros Biosciences AG is 396.66

What is the cash to sales ratio of Kuros Biosciences AG?

The cash to sales ratio of Kuros Biosciences AG is 6.43

What is the registered address of Kuros Biosciences AG?

The registered address for Kuros Biosciences AG is Wagistrasse 25, Schlieren, Zurich, 8952

What is the Kuros Biosciences AG website address?

The website address for Kuros Biosciences AG is kurosbio.com

bear777 4分前

I like the sound of Quantum X Corporation. Let us hope the delivery by the company is as good as the name chosen! Then it is "to the moon Alice!"

TWOH

ORCA 7分前

THE LAST TIME THE EMOJI GUY BRUSH THE STOCK 50 PLUS TIMES WAS WHEN THE STOCK WAS IN THE .003S TO .005S,HE BRUSHED IT THE SAME WAY.ORCA WAS ON THE BIDS BUYING MILLIONS UPON MILLIONS OF SHARES AND EVERYTIME MY BIG BLOCKS WHERE FILLED FROM TOO MUCH BRUSHING BY THE EMOJI GUY,I WAS LMAO.THE STUPID IDIOTS

BCDS

tdbowieknife 9分前

Wow.... Now they cooking.

LMAO...

.

.

Watch your wallet

Buyer Beware
Social Media Promoted Frontload Pump and Dump Share Selling Scam
http://images.investorshub.advfn.com/images/uploads/

IFUS

Eli's Gone 11分前

GL...

SeaBlue 19分前

I hope you are right. EOM

FFMGF

choo choo trader 19分前

WDDD/Gemaxel is on the Expert Market so most major brokerages will only allow you to sell and even then, you have to call them to place the order. When they get all their delinquent filings up to date, it should start trading again as a Pink Limited then it will be tradable with the brokers that all

WDDD

Makai63 19分前

Ok...you're definitely old!! 😂

ELTP

cojoboy 19分前

At this point no way to get outta this to even break even...no pps movement.. If I could sell at 2..I would in a heartbeat..🤗🤗🤗🤗

CGAC

mick 19分前

mcilroy --- mori gotterup clark fltw 275

SeaBlue 20分前

Are we the hamster on the wheel chasing the snack?

FFMGF

ORCA 20分前

From r/Daytrading, r/Pennystock, r/Stocktradingalerts +1 more
Exercise extreme caution with MEHA stock due to significant concerns about a potential "squeeze out" merger and possible securities law violations.

Proposed Acquisition and Shareholder Concerns
High Ownership

MEHA

stock king 1 21分前

For those that have known Steffan for over ten yrs know what he about . Do your dd or you will get burned

VXIT

TightCoil 21分前

Yahoo Finance
Ur-Energy (URG) Achieves Key Regulatory Milestone for Shirley Basin Project - 9 hours ago
HarianBasis.co
Ur-Energy Completes Regulatory Milestone for Shirley Basin Project - 6 hours ago
sekbernews.id
Ur-Energy Secures Approval for Wyoming Uranium Oper

URG

stock king 1 22分前

Both of those companies were garbage and let alone ran them over 20 billion shares

VXIT

DrivenByPain 22分前

Profile Data

Employees 86 as of 09/15/2025

https://www.otcmarkets.com/stock/SNTX/profile

🤑SNTX🤑 ➡️↗️⬆️

SNTX

stock king 1 23分前

People just look at what he did with Gtvh and hemp inc he burned so many people and imho laughed doing it

VXIT

stock king 1 23分前

It’s a shame because Steffan full of bull chit lies

VXIT

maddyandboomer 24分前

Wishful thinking....there are huge IFs and questions

AXXA

nowwhat2 26分前

https://investorshub.advfn.com/uimage/uploads/2026/7/12/lvvptbtc_july_12_capt_15d_7pm_PLEBES_.jpg

12 hrs earlier ; .........Juncture anticipated
https://investorshub.advfn.com/uimage/uploads/2026/7/12/fszlobtc_july_12_capt_15d_7am_200_FAN.jpg

htt

BTCUSD

11L1 26分前

https://stocktwits.com/Dirt_Nasty_Trades/message/658861634#:~:text=Bullish-,8%3A48%20PM,-3

FNMA

urge2surge 29分前

Authorized reduced to 100 million.

GNIS

Hawk05 29分前

AI can cause you to drink!!
It can’t figure out if the previous two posts are true or false!!!
Please assist in figuring out!!

BIEL

surfer44 29分前

The Evolution of Oil Tankers

https://youtu.be/uMZ9CkmzYMc

yadotn 31分前

MRNJ>>>1,694 Days

MRNJ
OTCMarkets
SEC Filings
FORM TYPE
1-A-POS
RECEIVED
November 13, 2023
"On November 22, 2021, we amended our Certificate of Incorporation to change our corporate name from Metatron Inc. to Metatron Apps, Inc. FINRA d

MRNJ

1kgwxman 32分前

There are no facts, proof or evidence Texas Tech's "name" is being misrepresented.
Just as there's no facts, proof or evidence Texas Tech is hooking up with an otc fusion scam.
Where's proof, not speculation, of the "bamboozle?"
😆

AMFN

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Kuros Biosciences AG (0RHR)

Kuros Biosciences AG (0RHR) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Kuros Biosciences AG について

0RHR 最新ニュース

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

0RHR - Frequently Asked Questions (FAQ)

0RHR 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する